Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Ophthotech Corp    OPHT   US6837451037

OPHTHOTECH CORP (OPHT)

3
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Ophthotech : Enters into Ex-US Licensing and Commercialization Agreement for Fovista® with Novartis

05/28/2014 | 11:58pm US/Eastern

By a News Reporter-Staff News Editor at Pharma Business Week -- Ophthotech Corporation (Nasdaq:OPHT) announced that the Company has entered into an ex-US licensing and commercialization agreement with Novartis Pharmaceuticals focused on the treatment of wet age-related macular degeneration (AMD). Under the agreement, Ophthotech grants Novartis exclusive rights to commercialize Ophthotech's lead product candidate, Fovista®, in markets outside the United States while Ophthotech retains sole rights to commercialize Fovista® in the United States. Potential payments to Ophthotech under the agreement could total over $1 billion in upfront and milestone payments, not including future royalties. Fovista® is the most advanced anti-PDGF agent in development for the treatment of wet AMD and, if approved, is expected to be first to market in this class of therapies for wet AMD (see also Pharmaceutical Companies).

Ophthotech will continue to lead the global Fovista® Phase 3 wet AMD pivotal clinical program which is expected to have initial, topline data available in 2016. Ophthotech will continue its lead role in the potential registration of Fovista® in the United States, while Ophthotech and Novartis will collaborate to seek regulatory approvals outside the United States.

This collaboration continues the Fovista® development strategy to remain agnostic with respect to the choice of the anti-VEGF agent administered in combination with Fovista®. Separate injections of the anti-VEGF agent and Fovista® would allow physicians to choose their preferred anti-VEGF agent for the combination therapy. The collaboration also provides for the potential development of a fixed combination delivery of a co-formulation of Fovista® with a Novartis proprietary anti-VEGF product which would result in additional flexibility for physicians. Novartis will also seek to develop and commercialize alternative innovative delivery technologies such as a Fovista® pre-filled syringe as part of this collaboration.

"As one of the largest ex-US partnering deals ever in the biotechnology industry, this collaboration with Novartis is potentially transformational for Ophthotech," stated David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board of Ophthotech. "This agreement represents an important achievement for the Company as we continue to execute on a strategy to deliver science-driven retinal products and offer physicians multiple treatment options to improve patient outcome. The collaboration also supports our previously stated plan to partner Fovista® outside the United States while we retain sole commercialization rights to Fovista® in the United States. The collaboration not only provides a substantial strategic and financial benefit to Ophthotech, it also begins to put in place essential elements designed to expand the reach of Fovista® outside the United States, following potential regulatory approvals."

Keywords for this news article include: Pharmaceutical Companies, Novartis AG, Ophthotech Corporation.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

(c) 2014 Pharma Business Week via NewsRx.com

Latest news on OPHTHOTECH CORP
10/06 OPHTHOTECH : Names Todd N. Smith as Chief Commercial Officer
10/03 OPHTHOTECH : Names Todd N. Smith as Chief Commercial Officer
09/25 OPHTHOTECH : Change in Directors or Principal Officers (form 8-K)
09/23 OPHTHOTECH : Names Michael G. Atieh as Executive Vice President and Chief Financ..
09/22 OPHTHOTECH : Change in Directors or Principal Officers (form 8-K)
09/16 OPHTHOTECH : Announces Fovista® Phase 2b Independent Analysis Shows that Fovista..
09/11 OPHTHOTECH : to Present at the 2014 Morgan Stanley Global Healthcare Conference
09/08 OPHTHOTECH : Achieves $50 Million Milestone under Ex-US Licensing and Commercial..
09/02 OPHTHOTECH : to Present at the 2014 Morgan Stanley Global Healthcare Conference
08/21 OPHTHOTECH : Initiates First of Several Expansion Studies to Further Evaluate Fo..
Advertisement
Chart
Duration : Period :
Ophthotech Corp Technical Analysis Chart | OPHT | US6837451037 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF